Influence of glial progenitor cells on the restoration of sensorimotor deficits in rats after traumatic brain injury

Relevance. The search for new methods of effective therapy for traumatic brain injury is one of the important tasks of modern biomedicine. One promising approach for treating traumatic brain injury is cell therapy. The aim of the work is to study the therapeutic effect of glial progenitor cells derived from induced pluripotent stromal cells in an experimental model of traumatic brain injury. Materials and Methods. Modeling of traumatic brain injury was carried out on mature male Wistar rats. The therapeutic group was administered a single dose of 750*103 cells/ml glial progenitor cells with a volume of 1 ml, and the control group — 1 ml of phosphate-­buffered saline. Administration was carried out intra-­arterially 24 hours after injury. To analyze the therapeutic effectiveness, an MRI study was performed on the 14th day, as well as a limb-placing test on the 1st, 3rd, 7th and 14th days. Histological examination was carried out on days 1, 3 and 7 after administration to assess the migration and distribution of stained cells (concentration 750*103 cells/ml) by lipophilic dye PKH26 (Sigma, USA) at the rat’s brain tissues after traumatic brain injury. Measurements of injury volume and counts of PKH26-stained cells were performed using ImageJ software (Wayne Rasband, National Institute of Mental Health, Bethesda, MD, USA). The statistical analysis was carried out using GraphPad Prism 8.2.0 program (GraphPad Software, Inc., USA). Results and Discussion. Administration of GPCs led to decreasing the damage volume. Significant decrease in sensorimotor deficit was observed on days 3, 7 and 14 after injury compared with the control group. Intra-arterial administration resulted in successful delivery of glial progenitor cells to brain tissue. Cells were detected in the cerebral cortex, hippocampus, and striatum on day 1, and were not observed on days 3 and 7 after administration. Conclusion. Intra-arterial administration of GPCs leads to efficient migration of cells into brain tissue. Glial progenitor cells therapy promotes neurorecovery processes after traumatic brain injury. This therapy is a promising treatment for traumatic brain injury.